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ARTHRITIS—Clinical Outcomes Studies
PAR1
RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG
THERAPY
Franic DM1, Kotzan JA1, Fagan SC1, Grauer DW2
1The University of Georgia, Athens, GA, USA; 2The University of
Kansas, Kansas City, KS, USA
OBJECTIVE: Rheumatoid arthritis (RA) was not considered a
fatal disease, however more recent evidence suggests increased
frequency of cerebrovascular events in RA patients, attributable
to factors beyond those explained in the general population. The
primary purpose of this study is to compare the incidence of new
cerebrovascular events in RA versus non-RA patients using ret-
rospective database accounting for traditional cardiovascular
(CV) risk factors. METHODS: RA patient cohort was identiﬁed
using ICD-9 diagnosis and prescription drug dispensed codes
from the Georgia Medicaid population database from 1999 to
2001. Cerebrovascular events were identiﬁed using ICD-9 codes
for: acute cardiovascular events; other cardiovascular events;
precerebral occlusions; and transischemic attacks (TIAs). A ran-
domized stratiﬁed matched case control analysis of RA versus
non-RA patients was performed based on age, sex, and race.
RESULTS: A sample of 11,842 was included in the study (5921
RA and 5921 non-RA): 44% were white, 80% female and 70%
were aged 21 to 64 years of age. Unadjusted contingency tables
showed the odds of someone having CV, TIA, other CV, and
occlusive disease was 1.58, 2.74, 3.00 and 2.46 times more likely
for a RA than a non-RA patient, respectively. CONCLUSION:
The results of this study supports earlier studies (Ricon et al
2001) showing that RA patients were at greater risk of 
cerebrovascular disease, however, further study is needed to
investigate the etiology. This could be beneﬁcial in designing 
preventative treatment strategies.
PAR2
INFLIXIMAB DOSING PATTERNS IN RHEUMATOLOGY
PRACTICES
Hendricks D, Callegari P, Ziskind M
Centocor Inc, Malvern, PA, USA
OBJECTIVES: Inﬂiximab, an antibody that binds to tumor
necrosis factor-alpha (TNF-alpha) is indicated for the treatment
of rheumatoid arthritis (RA). In August 2001, the prescribing
information for inﬂiximab in RA was broadened, allowing both
dose titration (3–10mg/kg) and infusion interval modiﬁcation
(every 4–8 weeks). A retrospective, observational study of inﬂix-
imab dosing patterns in rheumatology practices was conducted
to assess the impact of this label change. METHODS: Rheuma-
tology practices with multiple calls to the inﬂiximab Health Con-
nections Hotline were surveyed and participated (n = 40). Each
practice identiﬁed 3 patients pre-label change (group 1) and 3
patients post-label change (group 2) in a blinded, randomized
fashion. Data on demographics, insurance, diagnosis code, prior
medication use and inﬂiximab infusion history was collected.
RESULTS: Of 249 responses, 206 (82.7%) were evaluated and
analyzed with no statistical differences between groups 1 (n =
98) and 2 (n = 108). The median inﬂiximab dose in the induc-
tion phase and ﬁrst maintenance dose was 3.0mg/kg for both
groups. By maintenance dose 3, the group 1 median dose
remained at 3.0mg/kg while group 2 showed a nonsigniﬁcant
increase to 4.0mg/kg, although both groups reported signiﬁcant
steroid discontinuation. The mean number of vials administered
at this time was 3.2 (group 1) and 3.7 (group 2). The majority
(> 75%) of patients received £5mg/kg every 8 weeks by mainte-
nance dose 3. CONCLUSIONS: Dose ﬂexibility did not signiﬁ-
cantly increase inﬂiximab dose or decrease dosing interval in 
this cohort. The majority of RA patients receive an inﬂiximab
dose of £5mg/kg every 8 weeks with concomitant steroid 
discontinuation.
ARTHRITIS—Cost Studies
PAR3
ECONOMIC EVALUATION OF SELF-INJECTION VS
AMBULATORY CARE OF ANTI-RHEUMATOID BIOLOGICS
(ETANERCEPT) IN JAPAN
Igarashi A1, Fukuda T1,Tsutani K1, Miyasaka N2
1University of Tokyo, Bunkyo,Tokyo, Japan; 2Tokyo Medical and Dental
University,Tokyo, Bunkyo-ku, Japan
OBJECTIVE: To compare economic value of two administration
methods (self-injection and ambulatory care) of anti-rheumatoid
biologics (etanercept) by application of cost-effectiveness analy-
sis (CEA). METHODS: From A societal perspective, we gath-
ered cost data and outcome data. Cost data: 1) direct medical
cost: physician visit fee, injection fee, laboratory test fee, and in-
house self-injection guidance fee (from health insurance fee
schedule), drug costs (hypothetical costs—since etanercept is not
approved by Ministry of Health, Labour and Welfare yet); 2)
direct non-medical cost: transportation cost. Data were gained
from “Rheumatoid tomonokai”, RA patients organization in
Japan and teaching cost of self-injection. To estimate teaching
cost, we conducted a survey to health care provider; AND 3)
indirect cost: productivity loss. Outcome data: ACR20 gained
from 3rd phase of clinical trial data of etanercept in the Japan
and safety issues subject to self-injection, such as delayed ﬁnding
ADR, accidentally impale needles to other people, and so on.
Such data were gained from case report form (CRF). Because we
set the time horizon for analysis as 1 year, we did not apply dis-
count rate. We performed sensitivity analyses on 1) incidence of
ADR; 2) education cost; 3) frequency of hospital visit; AND 4)
productivity loss. RESULT: Effectiveness of self-injection care
and ambulatory care were considered to be similar. Adverse reac-
tion due to self-injection was not reported. Thus, we conducted
cost minimization analysis. Total cost of self-injection group
including indirect costs was JPY2,674,758 ($US22,746), which
was lower than that of ambulatory care group, JPY3,255,110
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($US27,682). CONCLUSION: As far as effectiveness, ambula-
tory care are the same. Self-injection therapy is preferable, espe-
cially including indirect costs.
PAR4
COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA
(TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN
RHEUMATOID ARTHRITIS
Spalding JR, Hay JW
University of Southern California, Los Angeles, CA, USA
Rheumatoid arthritis (RA) is an autoimmune disease with an
unknown etiology that results in over 9 million physician visits
and more than 250,000 hospitalizations per year. TNF-alpha
inhibitors are effective agents in treating RA. However, their
cost-effectiveness as ﬁrst-line agents has not been investigated.
OBJECTIVE: To examine the cost-effectiveness of using TNF-
alpha inhibitors as ﬁrst-line agents in rheumatoid arthritis from
a societal perspective, and secondly determine which of the
current TNF-alpha inhibitors is the most cost-effective in this
role. METHODS: A Markov model was developed utilizing a
discount rate of 3% and a lifetime time horizon for a hypothet-
ical cohort of United States females aged 55–60 who are diag-
nosed with RA. The source of data for predicted probabilities,
expected mortality rates, and treatment costs in year 2003
dollars (drug, toxicity, monitoring, and hospitalization) is from
the literature. These costs are assigned in ﬁve-year cycles along
with the effect on quality adjusted life years (QALY), which is a
function of the Health Assessment Questionnaire score. A sen-
sitivity analysis was conducted on all relevant parameters.
RESULTS: Etanercept was the most cost-effective TNF-alpha
inhibitor. It had an incremental cost-effectiveness ratio (ICER) of
$80,350 versus standard therapy. When taking into considera-
tion age of diagnosis and potential reduction in compliance-
related efﬁcacy with traditional DMARDS, the ICER varies from
$56,412 to $86,211. When assigned etanercept’s ﬁrst-line efﬁ-
cacy in the sensitivity analysis, adalimumab (ADAL) and inﬂix-
imab (INF) had ICERs of $82,783 and $65,881 versus standard
therapy, respectively. CONCLUSION: Depending where the
cost-effective threshold is drawn ($50,000–$100,000), etaner-
cept is relatively cost-effective versus standard care at $80,350.
ADAL and INF may also be cost-effective depending on results
of future head-to-head monotherapy trials.
PAR5
COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRATM) IN THE
TREATMENT OF US PATIENTS WITH RHEUMATOID
ARTHRITIS (RA)
Bansback N1, Brennan A1, Sengupta N2
1University of Shefﬁeld, Shefﬁeld, South Yorkshire, United Kingdom;
2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVE: Adalimumab is a new human TNF-antagonist
monoclonal antibody used to treat patients with moderate to
severe RA. We used an economic model to compare its cost effec-
tiveness to other biologic disease modifying anti-rheumatic drugs
(DMARDs) such as etanercept and inﬂiximab. METHODS:
Adhering to the US cost-effectiveness panel and AMCP guidance,
the model evaluated adalimumab with methotrexate (MTX) as
it would be given in typical practice. The analysis was performed
over 3 years from a payor’s perspective and is based on individ-
ual simulation of 10,000 RA patients. Patients’ clinical responses
were evaluated every six months. Probabilities were derived from
clinical (Phase III ARMADA trial) and long-term observational
databases. Costs included the drug, monitoring, administration,
RA-related hospitalization and treatment of adverse events.
Comprehensive sensitivity analyses were performed to highlight
key uncertainties. RESULTS: Using ACR50 clinical response
data, adalimumab + MTX resulted in a more sustained response
with a lower cost-effectiveness ratio compared to etanercept +
MTX and with inﬂiximab + MTX. Adalimumab data entered
into the 3-year model yielded ﬁndings that patients had 
1.36 years of good clinical response and a cost-effectiveness 
ratio of $45,600 per year of response. Results for etanercept 
+ MTX were 1.16 years and $53,900, while results for inﬂix-
imab + MTX were 0.69 years and $95,600. Sensitivity analysis
on clinical response conﬁdence intervals (CIs) revealed that cost-
effectiveness of the biologics overlapped, however CIs for adal-
imumab were narrower because of larger trial sample sizes.
CONCLUSION: Uncertainty in comparative efﬁcacy is currently
too large to deﬁnitively prove that one biologic DMARD is
always more cost-effective than the others, but larger sample
sizes in adalimumab trials give higher certainty regarding its efﬁ-
cacy. Since formulary decisions are made on data currently avail-
able, these results suggest that adalimumab + MTX is as cost
effective and possibly more cost effective than the other biologic
DMARDs.
PAR6
COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR
RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE
RESPONSE TO METHOTREXATE
Patel VD, Hay J
University of Southern California, Los Angeles, CA, USA
BACKGROUND: Several treatment options are now available
for rheumatoid arthritis patients that have inadequate response
to methotrexate alone. These agents are different in terms of
their efﬁcacy, safety, cost, and ease of administration. This 
makes it essential to perform a cost-effectiveness analysis taking
into account the important clinical and cost differences. This
model focuses on two combinations with proven efﬁcacy, in 
adequate well controlled trials, for patients with inadequate
response to methotrexate. OBJECTIVE: Compare 2-year cost-
effectiveness of two different treatment strategies, from the 
societal perspective, for rheumatoid arthritis patients with inad-
equate response to methotrexate: 1) Start patients on methotrex-
ate (MTX) + leﬂunomide (LEF), 2) Start patients on MTX +
tumor necrosis factor a (TNF-a). METHODS: A 2-year decision
analysis model with four semiannual cycles was developed to
estimate the average cost/QALY, and the incremental cost-effec-
tiveness ratio (ICER) for the two options, for female patients
with mean age of 50 years. The model input parameters such as;
response rates, dropout rates, costs, and QoL values were
obtained either from published literature, or from expert
opinion. Univariate sensitivity analysis was conducted to esti-
mate percent changes in ICER from the base case analysis with
change in gender, age, response rates, drug costs, and other para-
meters. RESULTS: The 2-year base case average cost/QALY is
$8,551 for patients started on MTX + LEF, and $19,340 for
patients started on MTX + TNF-a. The base case ICER for MTX
+ TNF-a is $36,147. In the univariate sensitivity analysis, ICERs
varied from $25,267 to $63,479. The model was extremely sen-
sitive to change in drug costs, and to the method used for con-
version of HAQ/QoL scores into QALYs. CONCLUSION: This
2-year cost-effectiveness model suggests that for patients with
inadequate response to methotrexate alone, the combination 
of MTX + TNF-a is a cost-effective strategy compared to MTX
+ LEF.
